💨 Abstract

A study of 170,000 U.S. adults with diabetes suggests that popular weight-loss medications like Wegovy, Ozempic, and Zepbound may slightly lower the risk of obesity-related cancers. The study compared these GLP-1 receptor agonists to other diabetes drugs and found a 7% lower risk of obesity-related cancers and an 8% lower risk of death from any cause in the GLP-1 group after four years.

Courtesy: WTOP Staff